文献速递心外重症与机械循环支持

2019冠状病毒病患者接受体外膜氧合支持后的生存差异:21个州49家医院594例连续病例的多机构分析

Variation in survival in patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation: A multi-institutional analysis of 594 consecutive patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation at 49 hospitals within 21 states.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-05-15

该多机构数据库分析了2020年3月17日至2021年12月20日期间49家医院594例接受体外膜氧合(ECMO)的2019冠状病毒病(COVID-19)患者,按4个时间段分组。出院时221例(37.2%)存活。研究期间中位年龄下降、诊断至插管天数增加,用药情况显著波动。贝叶斯混合效应逻辑回归显示生存估计比值比在研究期间有波动。

要点

  • 594例接受ECMO的COVID-19患者中,出院时221例(37.2%)存活,373例死亡。
  • 研究期间中位年龄从A组51.0岁降至D组39.0岁(P < .001)。
  • COVID-19诊断至插管的中位天数从A组4.0天增至D组9.0天(P < .001)。

核心结论

  • 接受ECMO支持的COVID-19患者生存率在大流行不同阶段出现波动。
  • 通过遵循最佳实践减少变异性可能优化ECMO在大流行应对中的使用。

研究设计与样本

  • 多机构数据库分析,纳入2020年3月17日至2021年12月20日期间49家医院21个州594例连续接受ECMO的COVID-19患者,并于2022年1月14日或之前脱离ECMO。
  • 按4个时间段分层:A组2020年3月至2020年6月,B组2020年7月至2020年12月,C组2021年1月至2021年6月,D组2021年7月至2021年12月。
  • 采用贝叶斯混合效应逻辑回归评估生存的连续趋势,以每位患者插管与2020年3月首例患者插管之间的天数作为时间变量,并控制多个变量和危险因素。

主要发现

  • 出院时594例中221例存活(37.2%),373例死亡。
  • 中位年龄[四分位距]下降:A组51.0[41.0-60.0]岁 vs D组39.0[32.0-48.0]岁,P < .001。
  • COVID-19诊断至插管的中位天数增加:A组4.0[1.0-8.5]天 vs D组9.0[5.0-14.5]天,P < .001。
  • 药物使用(糖皮质激素、白细胞介素-6阻断剂、抗病毒药、抗疟药)和恢复期血浆的使用显著波动(所有P < .05)。
  • 生存估计比值比在研究期间变化:2020年4月1日至2020年11月21日下降(比值比0.39,95%可信区间0.18-0.87,生存降低概率95.7%);2020年11月21日至2021年5月17日改善(比值比1.85,95%可信区间0.86-4.09,改善概率93.4%);2021年5月17日至2021年12月1日下降(比值比0.49,95%可信区间0.19-1.44,降低概率92.1%)。

临床怎么用

  • 作者认为,通过遵循最佳实践减少变异性可能优化ECMO在大流行应对中的使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We reviewed 594 consecutive patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation at 49 hospitals within 21 states and examined patient characteristics, treatments, and variation in outcomes over the course of the pandemic. METHODS: A multi-institutional database was used to assess all patients with Coronavirus Disease 2019 cannulated for extracorporeal membrane oxygenation between March 17, 2020, and December 20, 2021, inclusive, and separated from ECMO on or prior to January 14, 2022. Descriptive analysis was stratified by 4 time categories: group A = March 2020 to June 2020, group B = July 2020 to December 2020, group C = January 2021 to June 2021, group D = July 2021 to December 2021. A Bayesian mixed-effects logistic regression was used to assess continuous trends in survival where time was operationalized as the number of days between each patient's cannulation and that of the first patient in March 2020, controlling for multiple variables and risk factors. RESULTS: At hospital discharge, of 594 patients, 221 survived (37.2%) and 373 died. Throughout the study, median age [interquartile range] declined (group A = 51.0 [41.0-60.0] years, group D = 39.0 [32.0-48.0] years, P < .001); median days between Coronavirus Disease 2019 diagnosis and intubation increased (group A = 4.0 [1.0-8.5], group D = 9.0 [5.0-14.5], P < .001); and use of medications (glucocorticoids, interleukin-6 blockers, antivirals, antimalarials) and convalescent plasma fluctuated significantly (all P < .05). Estimated odds of survival varied over the study period with a decline between April 1, 2020, and November 21, 2020 (odds ratio, 0.39, 95% credible interval, 0.18-0.87, probability of reduction in survival = 95.7%), improvement between November 21, 2020, and May 17, 2021 (odds ratio, 1.85, 95% credible interval, 0.86-4.09, probability of improvement = 93.4%), and decline between May 17, 2021, and December 1, 2021 (odds ratio, 0.49, 95% credible interval, 0.19-1.44, probability of decrease = 92.1%). CONCLUSIONS: Survival for patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation has fluctuated during the stages of the pandemic. Minimizing variability by adherence to best practices may refine the optimal use of extracorporeal membrane oxygenation in a pandemic response.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Jacobs JP, Stammers AH, St Louis JD, et al. Variation in survival in patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation: A multi-institutional analysis of 594 consecutive patients with Coronavirus Disease 2019 supported with extracorporeal membrane oxygenation at 49 hospitals within 21 states. J Thorac Cardiovasc Surg. 2022. PMID: 36116956. doi:10.1016/j.jtcvs.2022.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。